Clinical Trials Logo

Colorectal Neoplasms clinical trials

View clinical trials related to Colorectal Neoplasms.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06376565 Not yet recruiting - Clinical trials for Colorectal Carcinoma

Improving Colonoscopy Surveillance for Patients With High Risk Colon Polyps

Start date: May 5, 2024
Phase: N/A
Study type: Interventional

This clinical trial tests a multilevel intervention at the clinic, provider and patient levels, to improve colonoscopy surveillance in patients with high risk colon polyps. Colorectal cancer (CRC) is a common and deadly disease that is largely preventable through the detection and removal of colorectal polyps. One million Americans are diagnosed with high risk polyps of the colon or rectum annually and are at increased risk for CRC; however, uptake of recommended repeat colonoscopy in 3 years to reduce CRC risk is low in this group. This multilevel intervention may work to improve timely colonoscopy screening for patients with high risk colon polyps.

NCT ID: NCT06373133 Not yet recruiting - Colorectal Cancer Clinical Trials

SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer

Start date: May 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate the efficacy and safety of SHR-8068 and Adebrelimab in Combination With Bevacizumabin in the treatment of microsatellite stable (MSS) advanced colorectal cancer.

NCT ID: NCT06370949 Not yet recruiting - Colorectal Cancer Clinical Trials

The Effectiveness of Bupivacaine and Bupivacaine+Dexmedetomidine Combination in Transversus Abdominis Plane* Block

TAP
Start date: May 1, 2024
Phase:
Study type: Observational

Transversus abdominis plane (TAP) block is an anesthesia method that provides somatic analgesia to the anterior and lateral abdominal walls. Thus, TAP block is widely implemented in perioperative management of colorectal cancer patients. Researchers aimed to evaluate the analgesic effectiveness and duration of effect of dexmedetomidine added to bupivacaine in the TAP block applied in colorectal cancer surgeries.

NCT ID: NCT06369259 Not yet recruiting - Clinical trials for Advanced Colorectal Cancer

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

Start date: October 31, 2024
Phase: Phase 2
Study type: Interventional

To learn if avutometinib in combination with defactinib and cetuximab can help to control unresectable, anti-EGFR-refractory, advanced colorectal cancer.

NCT ID: NCT06365970 Not yet recruiting - Clinical trials for MMR-D/MSI-H Colorectal Cancers

Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

Start date: May 31, 2024
Phase: Phase 2
Study type: Interventional

The second line of therapy for patients with MSI-H CRC who experience disease progression on anti-PD1 based therapies is not well defined and there is an unmet need for research for patients with anti-PD1 refractory MSI-H CRC. This study will examine the combination of niraparib and dostarlimab for a synergistic antitumor effect for patients with MSI-H CRC.

NCT ID: NCT06363552 Not yet recruiting - Clinical trials for Metastatic Colorectal Cancer

A Study of SC-0191 in Subjects With Metastatic Colorectal Cancer

Start date: May 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate the preliminary safety and efficacy of SC0191 as single agent or in combination with bevacizumab or 5-FU/LV in advanced colorectal cancer.

NCT ID: NCT06358430 Not yet recruiting - Colorectal Cancer Clinical Trials

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Start date: October 31, 2024
Phase: Phase 1
Study type: Interventional

To find the highest and/or recommended dose of TROP2-CAR-NK cells combined with cetuximab in participants with MRD CRC.

NCT ID: NCT06356714 Not yet recruiting - Colorectal Cancer Clinical Trials

Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Status

Start date: May 1, 2024
Phase: Phase 2
Study type: Interventional

Evaluate the efficacy and safety of Nocardia rubra cell wall skeleton in combination with prior second- or third-line regimens for the treatment of potentially hazardous colorectal cancer SD(Stable Disease) status in the real world.

NCT ID: NCT06351384 Not yet recruiting - Colorectal Cancer Clinical Trials

Early Detection and Risk Stratification of Colorectal Cancer Based on miRNA Platform

Start date: April 1, 2024
Phase:
Study type: Observational

This is a prospective, observational cohort study to establish the minimal residual disease (MRD) model for predicting relapse risk and identifying disease recurrence in patients with colorectal adenocarcinoma based on the miRNA platform. Blood miRNA markers will be evaluated. The study will enroll approximately 600 participants, including participants with malignancies or benign diseases, and healthy participants.

NCT ID: NCT06349642 Not yet recruiting - Clinical trials for Metastatic Malignant Solid Neoplasm

Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform

CYBRID-04
Start date: May 2024
Phase:
Study type: Observational

The primary purpose of this study is to determine the sensitivity of CYBRID Score for predicting in-vivo clinical response based on surgical response or RECIST 1.1 for neoadjuvant and locally advanced/metastatic patients, respectively. The secondary purposes is to determine the sensitivity of the CYBRID Score for predicting in-vivo clinical response based on surgical response or RECIST 1.1 for neoadjuvant and locally advanced/metastatic patients, respectively.